

SUPPLEMENTARY DATA

Supplementary Table 1. Baseline characteristics in patients with type 2 diabetes, with or without lipid lowering drugs.

	No lipid lowering drugs	drugs	P value
Numbers	10,627	7,704	
Lipid measures			
Total cholesterol (TC), mmol/L	5.20±0.94	4.85±1.01	<0.001
Non-HDL cholesterol, mmol/L	3.89±0.95	3.57±0.99	<0.001
LDL cholesterol, mmol/L	3.15±0.86	2.76±0.92	<0.001
HDL cholesterol, mmol/L	1.32±0.42	1.28±0.40	<0.001
Triacylglycerol (TG), mmol/L	1.63±0.76	1.81±0.79	<0.001
Ratio TC:HDL	4.25±1.28	4.03±1.22	<0.001
Ratio Non-HDL:HDL	3.25±1.28	3.03±1.22	<0.001
Ratio LDL:HDL	2.61±1.02	2.32±0.98	<0.001
Ratio TG:HDL	1.41±0.90	1.59±0.94	<0.001
Clinical features			
Age, years	59±8	61±7	<0.001
Diabetes duration, years	7±6	8±6	<0.001
HbA1c, %	7.2±1.2	7.3±1.2	<0.001
Systolic blood pressure, mmHg	140±18	141±17	<0.001
BMI, kg/m ²	29.5±5.3	29.7±4.8	0.003
Male gender	60.6	60.2	n.s.
Smoking	19.1	18.5	n.s.
Albuminuria >20 µg/min	17.3	23.1	<0.001
History of cardiovascular disease	6.1	23.3	<0.001
Hypoglycaemic treatment			
Diet only	26.7	17.8	<0.001
Oral agents only	38.0	39.4	n.s.
Oral agents and insulin	14.1	22.9	<0.001
Insulin only	21.2	19.9	0.04

Means ± SD and frequencies (%) are given.

SUPPLEMENTARY DATA

Supplementary Table 2. Hazard ratios for different lipid measures and fatal/nonfatal coronary heart disease at Cox regression, in 10,627 type 2 diabetic patients with no lipid lowering drugs and 578 CHD events, and 7,704 patients with lipid lowering drugs and 561 events, followed for five years.

	No lipid lowering drugs			Lipid lowering drugs		
	Hazard ratio * (95% CI)	Wald X^2	P value	Hazard ratio * (95% CI)	Wald X^2	P value
Lipid measures						
TC:HDL	1.27 (1.17-1.37)	35	<0.001	1.19 (1.09-1.28)	17	<0.001
Non-HDL:HDL	1.27 (1.17-1.37)	35	<0.001	1.19 (1.09-1.28)	17	<0.001
LDL:HDL	1.25 (1.16-1.35)	32	<0.001	1.18 (1.09-1.27)	17	<0.001
Non-HDL	1.22 (1.13-1.33)	23	<0.001	1.18 (1.09-1.28)	16	<0.001
TG:HDL	1.18 (1.09-1.27)	17	<0.001	1.10 (1.01-1.19)	5.1	0.02
LDL	1.18 (1.09-1.28)	16	<0.001	1.16 (1.07-1.26)	13	<0.001
TC	1.15 (1.06-1.25)	12	<0.001	1.13 (1.04-1.23)	8.6	<0.001
HDL	0.84 (0.76-0.93)	11	<0.001	0.87 (0.79-0.96)	7.4	0.006
TG	1.14 (1.05-1.24)	10	0.002	1.09 (0.99-1.18)	3.7	0.55
Combinations:						
LDL	1.18 (1.09-1.28)	15	<0.001	1.16 (1.07-1.26)	13	<0.001
TG:HDL	1.18 (1.09-1.27)	16	<0.001	1.10 (1.02-1.20)	5.5	0.02

Abbreviations: TC: total cholesterol; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; TG: triacylglycerol; CI: confidence interval.

* Cox proportional hazards regression for a 1 SD increase in a lipid measure, with adjustment for age, sex, diabetes duration, type of hypoglycaemic treatment, HbA1c, systolic blood pressure, smoking, BMI, albuminuria >20 µg/min and a history of CVD. Wald X^2 statistics (a higher value indicates stronger association) and P values are given.

SUPPLEMENTARY DATA

Supplementary Table 3. Comparison of triacylglycerol and HDL-cholesterol by various subgroups of lipid measures.

	Tertile 1 of lipid measures				P for trend
	Non-HDL:HDL	LDL:HDL	Non-HDL	LDL	
	<2.5 (n = 6,180)	<2.0 (n=6,225)	<3.3 mmol/L (n = 6,079)	<2.5 mmol/L (n = 6,224)	
TG:HDL					
Mean (SD)	0.82±0.47	1.04±0.75	1.15±0.81	1.49±1.03	<0.001
Median (25 th – 75 th)	0.72 (0.50 – 1.0)	0.81 (0.50 – 1.31)	0.92 (0.57 – 1.47)	1.21 (0.71 – 2.0)	
TG, mmol/L					
Mean (SD)	1.25±0.58	1.46±0.76	1.37±0.67	1.69±0.83	<0.001
Median (25 th – 75 th)	1.10 (0.80 – 1.50)	1.30 (0.90 – 1.90)	1.20 (0.90 – 1.70)	1.50 (1.0 – 2.20)	
HDL, mmol/L					
Mean (SD)	1.66±0.45	1.62±0.48	1.41±0.52	1.35±0.51	<0.001
Median (25 th – 75 th)	1.60 (1.40 – 1.90)	1.54 (1.30 – 1.89)	1.30 (1.07 – 1.69)	1.20 (1.0 – 1.58)	

Abbreviations: TG: triacylglycerol. HDL: high-density lipoprotein cholesterol. TG:HDL: ratio of triacylglycerol-to-HDL-cholesterol. P for trend by GLM regression.